Zacks: Analysts Anticipate Merus NV (MRUS) Will Post Quarterly Sales of $7.57 Million
Brokerages expect Merus NV (NASDAQ:MRUS) to post sales of $7.57 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Merus’ earnings, with the lowest sales estimate coming in at $4.66 million and the highest estimate coming in at $10.47 million. Merus posted sales of $7.81 million in the same quarter last year, which suggests a negative year over year growth rate of 3.1%. The firm is scheduled to announce its next earnings results on Thursday, July 25th.
On average, analysts expect that Merus will report full year sales of $29.91 million for the current financial year, with estimates ranging from $18.62 million to $41.19 million. For the next financial year, analysts anticipate that the firm will post sales of $49.95 million, with estimates ranging from $18.62 million to $81.28 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Merus.
Merus (NASDAQ:MRUS) last posted its earnings results on Wednesday, April 3rd. The biotechnology company reported ($0.34) earnings per share for the quarter. Merus had a negative net margin of 75.71% and a negative return on equity of 38.79%. The firm had revenue of $9.67 million during the quarter.
Merus stock opened at $13.90 on Monday. Merus has a fifty-two week low of $11.00 and a fifty-two week high of $26.74. The stock has a market capitalization of $307.14 million, a PE ratio of -7.55 and a beta of -0.05.
A number of hedge funds have recently modified their holdings of MRUS. Aquilo Capital Management LLC increased its position in Merus by 3.6% in the 3rd quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock valued at $25,577,000 after acquiring an additional 44,799 shares during the period. Morgan Stanley increased its position in Merus by 74.3% in the 3rd quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after acquiring an additional 30,538 shares during the period. Artal Group S.A. acquired a new position in Merus in the 4th quarter valued at about $2,886,000. Geode Capital Management LLC increased its position in Merus by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 2,373 shares during the period. Finally, Squarepoint Ops LLC increased its position in Merus by 10.3% in the 4th quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 1,100 shares during the period. Hedge funds and other institutional investors own 52.13% of the company’s stock.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.